TAMPA, Fla.--(BUSINESS WIRE)--Dec. 12, 2005--Accentia Biopharmaceuticals, Inc. (Accentia) (NASDAQ:ABPI) announced today the publication of a pharmacokinetic (PK) study regarding Emezine(R) (prochlorperazine maleate) a buccal tablet being developed for the intended treatment of severe nausea and vomiting (emesis). The findings, published in the December 2005 issue of the Journal of Clinical Pharmacology, demonstrated that the mucosa absorption of Emezine buccal tablet delivered more than twice the plasma concentrations of the active ingredient, prochlorperazine, with significantly less intra-patient variability than that obtained from a standard oral swallow tablet.
